DIVI'S LABORATORIES LIMITED
Press Release dated 7th November, 2020
The group is engaged in the manufacture of Active Pharmaceutical Ingredients, intermediates, and nutraceutical ingredients.
MANAGEMENT
Dr.Murali K.Divi : Managing Director
N.V.Ramana : Executive Director
kiran S.Divi : CEO & whole time director
Ramesh B.V.Nimmagadda : Non Executive Chairman &
Independent Director
Consolidated Results
|
DIVIS |
Q2 FY21 |
Q1 FY 21 |
Q2 FY 20 |
YOY |
QOQ |
|
TOTAL INCOME |
1762.94 |
1747.8 |
1445.57 |
21.95 |
0.87 |
|
TOTAL EXP |
1069.45 |
1086.82 |
1004.73 |
6.44 |
-1.6 |
|
PBT |
693.49 |
660.98 |
487.87 |
42.15 |
4.92 |
|
NET PROFIT |
519.59 |
492.06 |
356.78 |
45.63 |
5.59 |
|
COMP.INCOME |
521.11 |
492.1 |
359.72 |
44.87 |
5.9 |
|
EQUITY |
53.09 |
53.09 |
5309 |
-99 |
0 |
|
BASIC EPS |
19.57 |
18.54 |
13.44 |
45.61 |
5.56 |
|
CASH FLOWS |
HY1 FY21 |
HY1 FY 20 |
YE 31.03.20 |
||
|
NCF.F.OPRTG |
1157.62 |
356.9 |
1215.94 |
||
|
NCF.F.INVESY |
579.82 |
293.65 |
-83.47 |
||
|
NCF.F.FINANC |
-33.97 |
-597.34 |
-1091.42 |
||
|
CASH&CE AT END |
1746.62 |
55.31 |
43.15 |
||
NOTE :
Proceeds out of sale of Investments : 974.00 :979.75:1483.63
Divi's Laboratories has earned a consolidated total income of Rs.1763 crores for quarter ended 30th September, 2020 as against a consolidated total income of Rs.1493 crores in the corresponding quarter of the previous year.
Profit before Tax (PBT) for the quarter grew by 42% to Rs. 693 crores as against a PBT of Rs.488 crores for the corresponding quarter of the last year.
Profit after Tax (PAT) for the quarter grew by 46% to Rs. 520 crores as against a PAT of Rs.357 crores for the corresponding quarter of the last year.
For the current quarter, Company has a forex loss of Rs.16 crores as against a gain of Rs.13 crores during the Standalone Results
On a standalone basis, the company's earnings are as given below: (Rs.in crores)
Particulars For Q2 FY21 Q/E Q2 FY 20 H.Y.E SEP20 HYE SEP10
Total Income :1727 : 1451 : 3450 : 2617
PBT : 685 : 483 : 1346 : 849
PAT : 513 : 353 : 1006 : 620
Forex Gain/loss} Particulars of forex gain/(loss) for the period are given below: (Rs.in crores)
Particulars Q2 FY 21 : Q2 FY 20 : H.Y.E SEP20; H.Y.E SEP 19
Forex gain/(loss) : (12) : 13 : (7) : 7
The company has been able to have near normal operations during the quarter.
Capex Programs :
Divi's have capitalized assets of Rs.615 crores during the quarter and the total capitalization done during the half-year amounted to Rs.830 crores.
Divis expects to complete the ongoing capex programs by end of the financial year. Apart from the existing capex programs, the Company is taking up a new capex for an aggregate amount of Rs.400 crores for meeting new business opportunities in the custom synthesis projects; and needed to be completed on fast track.
The Group has not experienced any significant impact on its operations, supply chain and recoverability of carrying amounts of financial and non-financial assets due to COVID 19 pandemic. As the pandemic continues to evolve, the Group will continue to closely monitor for any material changes to future economic conditions.
The consolidated unaudited results include the financial results of Divi's Laboratories Limited and its two subsidiaries Divis Laboratories (USA) Inc. and Divi's Laboratories Europe AG.
ANNUAL REPORT 2019-20
2019 : Significant expansion of manufacturing facilities began with an 1800 Cr investment
Divi's is among the largest API manufacturers in the world
Portfolio of 122 products
FY 2019-20 snapshot
Total revenue ; Rs.5500.43 Cr(9%)
EBITDA : Rs.2005.30 Cr
PBT : Rs.1813.29 (-1%)
PAT : Rs.1372.71 (+3%)
EPS (FV. Rs.2) : Rs.51.71 (+3.01%)
We have yet another year of successful operations during FY2019-20. Focus this year has been on completing the large capex programs taken up during the year, which comprised two brownfield projects, besides de-bottlenecking/ backward integration and utilities expansion projects.
Exports constituted 87% of sales revenue during the year. Exports to advanced markets comprising Europe and America accounted for 71% of business.
region-wise sales percentage
Region : 2019-20 : 2018-19
Asia 11.4%(12.5%)
Europe 48%(45.9%)
America 23.4%(26.8%)
Rest of the World 4.1% (2.9%)
India 13.1%(11.9%)
Total 100.0%
Capital Expenditure
Divis have taken up two brownfield projects called DCV SEZ Unit at village Chippada, Bheemunipatnam Mandal, Visakhapatnam and DC SEZ Unit at village Lingojigudem, Choutuppal Mandal, Yadadri Bhuvangiri District, Telangana with an estimated investment of `600 crores each.
Besides this, Divis have also taken up debottlenecking, backward integration and utilities expansion projects at both the manufacturing sites.
The Company has commenced commercial operations from a part of the DC-SEZ Unit in February, 2020, and from a part of the DCV-SEZ Unit in March, 2020.
A part of the backward integration, debottlenecking and utility expansion projects have come into utilization this year. The rest of these projects will be completed and come into utilization by end of second half of financial year 2020-21.
The balance works of the brownfield projects of DC-SEZ and DCV-SEZ are also expected to be completed by second half of financial year 2020-21.
During the year, we have capitalized PPE and Intangible Assets valuing `878.38 Cr. WIP as at the year-end amounted to `919.69 Cr.
Key Financial Ratios
Particulars 31-03-20 31-03-19 Change
Return on Net Worth (%) 18.76%19.11% (2)%
Return on Capital Employed (%) 27.79%30.62%(9)%
Basic EPS (after exceptional items) (`) 51.71 50.20 3%
Debtors Turnover 3.91 4.21 (7)%
Inventory Turnover 3.23 3.42 (6)%
Current ratio 5.16 5.58 (8)%
Debt Equity ratio 0.005 0.015 (69)%
Operating profit margin (%) 36.46%39.82%(8)%
Net profit margin (%) 24.96% 26.46% (6)%
|
COMPANY |
DETAILS |
Sep '20 |
Jun '20 |
Sep '19 |
YOY |
QOQ |
|
AARTI DRUGS |
Net Sales |
578.11 |
544.67 |
477.5 |
21.07 |
6.14 |
|
Net PROFIT |
75.27 |
85.45 |
32.31 |
132.96 |
-11.91 |
|
|
IF FV-2,EPS = 6.4 |
Basic EPS |
32.3 |
36.67 |
13.87 |
132.88 |
-11.92 |
|
FV |
10 |
|||||
|
MP =150 |
MP |
750 |
||||
|
5.8 |
PE |
5.8 |
||||
|
LAURUS Labs |
Total Income |
1,143 |
981 |
713 |
60.22 |
16.62 |
|
Net Profit |
242 |
171 |
56 |
324.56 |
40.7 |
|
|
Basic EPS |
4.53 |
16.07 |
5.31 |
327.36 |
41.12 |
|
|
FV |
2 |
|||||
|
MP |
270 |
|||||
|
PE |
14.9 |
|||||
|
DIVIS |
Sales |
1,730 |
1,389 |
1,162 |
21.95 |
0.87 |
|
Net Profit |
492 |
388 |
272 |
45.63 |
5.59 |
|
|
Basic EPS |
18.54 |
14.62 |
10.26 |
|||
|
FV |
2 |
|||||
|
MP |
3237 |
|||||
|
PE |
43.65 |
No comments:
Post a Comment